Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer - Episode 1
Jonathan W. Riess, MD, MS:This is a 69-year-old woman who presented with dyspnea, cough, and fatigue in March of 2017. She was evaluated with a chest X-ray that showed a lung mass. Biopsy showed nonsmall cell lung cancer, adenocarcinoma histology. The patient had an MRI that was negative for intracranial metastatic disease. She had molecular testing that was positive, through a next-generation sequencing panel, for anALKrearrangement but negative forEGFR,ROS1,BRAF,and other molecular aberrations. She was started on crizotinib, with initial response to treatment at 3 months and at 6 months.
So, in January of 2018, the patient developed worsened cough, dyspnea, and bone lesions. Imaging studies showed worsening lymph nodes and bone lesions. MRI of the brain showed disseminated brain metastases, and crizotinib was discontinued. The patient was started on brigatinib.
Transcript edited for clarity.
CASE:ALK+ NonSmall Cell Lung Cancer